Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®.
- Trial name
- NCT04698018
- Testing
- Faster Aspart, Novo Rapid
- Where
- 3 sites in Germany, Hong Kong
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Type1diabetes
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with…
- Trial name
- NCT04028960
- Testing
- Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of…
- Trial name
- NCT04096794
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Xiangya Hospital of Central South University
Hypertension, Cardiovascular Diseases
OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of…
- Trial name
- NCT00134160
- Testing
- Olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
- Where
- 2 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- OSCAR Study
Type1 Diabetes Mellitus
Chinese Smartphone App for 6-18 Years With T1DM - RCT
Moving into the era of electronic communication, it changes the way we shall engage our children and adolescents. According to data of the Census and Statistics Department of Hong Kong releases in 2019, more than 80% and up to…
- Trial name
- NCT05418569
- Testing
- Intervention arm - A new smartphone application for pediatric type 1 DM, Standard diabetic eduction
- Where
- Hong Kong
- Volunteers
- 114 people
- Sponsor
- Chinese University of Hong Kong
CTLA4 Haploinsufficiency
Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency
CTLA4 and LRBA deficiencies are rare genetic disorders, recently described, and associated with multiple clinical features. It ranges from recurrent infections, auto-immunity, and organ infiltration with lymphocytes.
- Trial name
- NCT05040256
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Type 1 Diabetes
The International Diabetes Closed Loop (iDCL) Trial: Protocol 4
The investigators aim to compare the efficacy and safety of an AID system using an adaptive MPC algorithm versus SAP (which may or may not include PLGS; to be referred to as SAP) in people with type 1 diabetes.
- Trial name
- DCLP4 (NCT04436796)
- Testing
- interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sansum Diabetes Research Institute
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 1
Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults
This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults.
- Trial name
- NCT03945903
- Testing
- Golimumab
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Type 1 Diabetes
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).
- Trial name
- NCT02018627
- Testing
- Xeris glucagon, Lilly glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Steven J. Russell, MD, PhD
Diabetes Mellitus, Type 1
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
This study is a randomized, controlled trial to evaluate the efficacy and safety of the Omnipod® 5 System with the FreeStyle Libre 2 continuous glucose monitor compared to Multiple Daily Injections (MDI) along with the FreeStyle…
- Trial name
- RADIANT (NCT05923827)
- Testing
- Omnipod 5 System
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 189 people
- Sponsor
- Insulet Corporation
Diabetes Type 1
Optimising the Delivery of Diabetes Distress Informed Care for Its Prevention, Detection, and Management in Adults With Type 1 Diabetes: a Feasibility Study (D-stress Study)
Up to one in two adults with type 1 diabetes find living with and managing diabetes to be emotionally challenging. This 'emotional side' of diabetes - feeling worried, frustrated, overwhelmed, sad, burnt-out - is called diabetes…
- Trial name
- NCT07193446
- Testing
- D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.
- Where
- 3 sites in United Kingdom
- Volunteers
- 110 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Type 1 Diabetes
BeAT1D: Benign Autoimmunity and Type 1 Diabetes
National multi-center non-interventional case-control cohort study with collection of biological samples to characterize the autoimmune T and B lymphocytes involved in the development of type 1 diabetes.
- Trial name
- BeAT1D (NCT05139784)
- Testing
- Biosampling
- Where
- 17 sites in France
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Diabetic Foot Ulcer
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
This prospective, multi-center, randomized, controlled modified platform Trial compares Purified Native Type 1 Collagen Extracellular Matrix with Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care versus…
- Trial name
- PREPARE (NCT06618612)
- Testing
- Standard of Care, PuraPly AM, PuraPly XT
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Organogenesis
Type 1 Diabetes, Diabetic Ketoacidosis
Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
Type 1 Diabetes is characterized by an absolute lack of insulin caused by autoimmune ß-cell destruction. Looking for different therapeutic approaches, beyond the administration of Insulin SGLT-Inhibitors (SGLT=sodium-glucose…
- Trial name
- Dapa-Stress (NCT04234867)
- Testing
- Dapagliflozin, Stress
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Kinderkrankenhaus auf der Bult
Type 1 Diabetes, Type 2 Diabetes
Remote Monitoring in Diabetes Disease Management
The primary objective of this study is to determine whether remote monitoring in diabetes management is more effective at helping patients manage their disease than a standard disease management program.
- Trial name
- NCT00675311
- Testing
- DM-Standard, Disease Management Plus
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- LifeScan
Diabetes Mellitus
Ramadan Flash Glucose Monitoring Study
Many Muslim patients with diabetes observe dawn to sunset fasting during the month of Ramadan. Hyperglycaemia and hypoglycaemia are possible problems amongst these patients.
- Trial name
- RFGM (NCT04356898)
- Testing
- No intervention
- Where
- 2 sites in United Arab Emirates
- Volunteers
- 321 people
- Sponsor
- Imperial College London Diabetes Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.